Rankings
▼
Calendar
CTMX Q3 2025 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$846M
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$6M
-82.2% YoY
Gross Profit
$6M
100.0% margin
Operating Income
-$16M
-264.4% margin
Net Income
-$14M
-238.6% margin
EPS (Diluted)
$-0.09
QoQ Revenue Growth
-68.0%
Cash Flow
Operating Cash Flow
-$16M
Free Cash Flow
-$15M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$158M
Total Liabilities
$51M
Stockholders' Equity
$107M
Cash & Equivalents
$34M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$6M
$33M
-82.2%
Gross Profit
$6M
$33M
-82.2%
Operating Income
-$16M
$4M
-483.6%
Net Income
-$14M
$6M
-348.1%
← Q2 2025
All Quarters